CJC-1295 DAC 2mg is a long-acting GHRH analog studied for raising GH and IGF-1. Learn about research dosing, differences from no-DAC, and safety.
CJC-1295 DAC 2mg refers to a 2-milligram vial of a long-acting growth hormone-releasing hormone (GHRH) analog. The DAC modification binds the peptide to albumin in the blood and extends its half-life to roughly 6–8 days. This article explains what the peptide is, how it differs from CJC-1295 without DAC, typical research dosing, and safety considerations.
What Is CJC-1295 DAC 2mg?
CJC-1295 DAC is a synthetic analog of growth hormone-releasing hormone. It contains four amino acid substitutions that increase its stability and receptor affinity compared with natural GHRH.
The 2mg designation tells you the amount of lyophilized powder in a single vial. Researchers typically reconstitute the powder with bacteriostatic water before use.
The abbreviation cjc 1295 with dac 2mg is often used interchangeably with CJC-1295 DAC 2mg in research discussions. The DAC stands for Drug Affinity Complex, a maleimide-based linker that covalently attaches to serum albumin.
This albumin binding protects the peptide from rapid enzymatic degradation. CJC-1295 DAC is not approved by the FDA for human use and is sold as a research chemical for laboratory study only.
How CJC-1295 DAC Works in the Body
CJC-1295 DAC binds to GHRH receptors on the pituitary gland. This binding stimulates the release of growth hormone (GH) in a pulsatile manner that mimics natural secretion.
Because the DAC modification extends its half-life, a single dose can sustain elevated GH levels for several days. This is different from shorter-acting GHRH analogs, which require more frequent administration.
Increased GH can raise insulin-like growth factor 1 (IGF-1) produced by the liver. IGF-1 mediates many of the growth-promoting and metabolic effects attributed to GH.
Most research on CJC-1295 has focused on its pharmacokinetics and its ability to raise IGF-1 in healthy adults. Long-term safety data in humans remain limited.
Typical CJC-1295 DAC 2mg Dosage in Research
There is no established human dosage for CJC-1295 DAC. Any numbers below come from published research protocols or informal reports, not from FDA-approved prescribing information.
In a commonly cited clinical study, participants received 1mg to 2mg of CJC-1295 DAC per week. The half-life of about 6–8 days supports once-weekly or twice-monthly dosing in research settings.
When researchers look up cjc-1295 with dac 2mg dosage, they often find ranges of 1mg to 2mg per week. Some protocols split the dose into two 1mg injections per week to reduce peak effects.
When researchers compare cjc 1295 dac 2mg dosage protocols, the most consistent finding is that higher doses produce larger IGF-1 increases but also more side effects.
Do not confuse CJC-1295 DAC with CJC-1295 without DAC. The no-DAC version has a much shorter half-life and is typically dosed at 100mcg two to three times daily.
| Form | Half-life | Typical research dose | Frequency |
|---|---|---|---|
| CJC-1295 DAC | ~6–8 days | 1–2mg | Once weekly or every 2 weeks |
| CJC-1295 No DAC (Mod GRF 1-29) | ~30 minutes | 100mcg | 2–3 times daily |
CJC-1295 DAC vs CJC-1295 No DAC
The main difference between the two forms is half-life. CJC-1295 DAC stays active for days, while CJC-1295 No DAC is cleared within about 30 minutes.
Because of the short half-life, cjc-1295 no dac; mod grf 1-29 is often injected multiple times a day to mimic natural GH pulses. The DAC version produces a sustained, non-pulsatile elevation of GH.
Some researchers prefer the no-DAC form for its more physiological pulse pattern. Others choose the DAC form for convenience and fewer injections.
A cjc-1295 no dac 2mg vial contains the same amount of powder as the DAC version, but the dosing schedule is completely different.
Safety, Side Effects, and Legal Status
CJC-1295 DAC is not approved by the FDA for human use in the United States. It is not legal to sell as a supplement or prescription drug, and it is intended for laboratory research only.
Reported side effects from GH-releasing peptides include injection site reactions, joint pain, swelling, headache, and fatigue. These effects are usually mild but can vary by dose and individual sensitivity.
Elevated GH and IGF-1 over long periods may carry risks such as insulin resistance, fluid retention, and potential effects on growth of abnormal tissues. Human safety data for CJC-1295 DAC are insufficient to rule out harm.
Anyone considering any peptide for personal use should consult a licensed healthcare professional. Self-administering research chemicals is risky and not recommended.
Storage and Handling of 2mg Vials
Lyophilized CJC-1295 DAC 2mg vials should be stored in a freezer at -20°C or colder, protected from light. Keep the powder dry until you are ready to reconstitute it.
After reconstitution with bacteriostatic water, store the vial in a refrigerator at 2–8°C. Most peptides remain stable for several weeks under these conditions, but check the supplier’s documentation.
Avoid repeated freeze-thaw cycles. They can degrade the peptide and reduce its potency. Handle vials with clean technique to prevent bacterial contamination.
Key Takeaways
- CJC-1295 DAC 2mg is a long-acting GHRH analog supplied as a 2mg research vial.
- The DAC modification extends half-life to about 6–8 days by binding to albumin.
- Typical research doses range from 1mg to 2mg per week, but no human dose is approved.
- CJC-1295 No DAC has a much shorter half-life and is dosed multiple times daily.
- CJC-1295 DAC is not FDA-approved and is intended for laboratory research only.
Frequently Asked Questions
What is CJC-1295 DAC 2mg?
CJC-1295 DAC 2mg is a 2-milligram vial of a long-acting growth hormone-releasing hormone analog. The DAC modification binds the peptide to albumin and extends its half-life to about 6–8 days. It is sold as a research chemical, not as an FDA-approved medication.
How is CJC-1295 DAC 2mg dosed in research?
Published research protocols often use 1mg to 2mg per week because of the long half-life. Some studies split the dose into two 1mg injections. No human dose has been established by the FDA, and self-dosing is not recommended.
Is CJC-1295 DAC 2mg legal and safe?
CJC-1295 DAC is not FDA-approved for human use in the United States. It is intended for laboratory research only, and its long-term safety in humans is unknown. Consult a licensed healthcare professional before considering any peptide for personal use.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.